The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Background: A consensus has not been reached about the optimal duration of oral anticoagulant therapy after a second episode of venous thromboembolism.

Methods: In a multicenter trial, we compared six months of oral anticoagulant therapy with anticoagulant therapy continued indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 patients enrolled, 111 were randomly assigned to six months of anticoagulation and 116 were assigned to receive anticoagulant therapy indefinitely; for both groups, the target international normalized ratio was 2.

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Background: The optimal duration of oral anticoagulant therapy after a first episode of venous thromboembolism is still a matter of debate.

Methods: We performed a multicenter trial comparing six weeks of oral anticoagulant treatment with six months of such therapy in patients who had a first episode of venous thromboembolism. Anticoagulant therapy consisted of warfarin or dicumarol.

Early diagnosis of acute myocardial infarction. A comparison between chemical predictors.

Consecutive patients (n = 155) admitted to coronary care units at three different hospitals were investigated. The overall prevalence of acute myocardial infarction (AMI) was 0.45.

Complexity of enzyme release during acute myocardial infarction in a controlled study with early nifedipine treatment.

Fifty-seven consecutive patients with acute myocardial infarction (AMI), admitted to a coronary care unit (CCU) within 6 h from onset of symptoms were included in the study and randomly allocated to nifedipine treatment or placebo. The 23 patients in the treatment group received 10 mg nifedipine orally at the onset of the study, after 30 min, and then every 6 h. Placebo was given to the 34 patients in the control group.